AACR 2022: Evaluating In Vivo Efficacy of Anti-VSIG4 Antibodies in Humanized B-hVSIG4 Mice
Conclusions
- We have generated a humanized mouse model expressing human VSIG4 in place of the murine counterpart.
- mRNA and protein expression of human VSIG4 indicates successful generation of the humanized model.
- Humanization of VSIG4 does not change the overall development, differentiation or distribution of immune cell types in spleen, lymph node and blood.
- Anti-VSIG4 antibody treatment reduced tumor growth in B-VSIG4 mice, indicating that B-VSIG4 mice are a powerful model for evaluation of anti-human VSIG4 antibodies.
Related mouse model: B-hVSIG4 mice
